Cellular suicide therapy of malignant disease

Stem Cells

Volumn 18, Issue 3, 2000, Pages 220-226

  Link, Charles J ^a,b   Seregina, Tatinia ^a,b   Traynor, Ann ^a,b   Burt, Richard K ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Iowa Cancer Research Foundation   (United States)

Author keywords

Adoptive cellular therapy; Allogeneic; Donor lymphocyte infusion; Suicide gene; Vector producing cells; Xenogeneic

Indexed keywords

GANCICLOVIR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; GENE TARGETING; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MOUSE; NONHUMAN; OVARY CANCER; SUICIDE GENE; XENOGRAFT;

ANIMALIA;

EID: 0034043882     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.18-3-220     Document Type: Article

References (33)

1. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
2. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993;82:2310-2318.
3. Bordignon C, Bonini C, Verzeletti S et al. Transfer of HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 1995;6:813-819.
4. Tiberghien P, Cahn JY, Milpied N et al. Administration of donor T-cells expressing Herpes simplex thymidine kinase gene in conjunction with a T-cell depleted allogeneic marrow graft. Blood 1996;10:272a.
5. Link CJ Jr, Burt RK, Traynor AE et al. Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. Hum Gene Ther 1998;9:115-134.
6. Ram Z, Culver KW, Oshiro EM et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354-1361.
7. Link CJ, Moorman D, Seregina T et al. Recombinant DNA Advisory Committee Meeting, March 6 and 7, 1995; Federal Register, Bethesda, MD.
8. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-5281.
9. Plautz G, Nabel EG, Nabel GJ. Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biol 1991;3:709-715.
10. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-4242.
11. Bonini C, Bordignon C. Potential and limitations of HSV-TK-transduced donor peripheral blood lymphocytes after allo-BMT. Hematol Cell Ther 1997;39:273-274.
12. Riddell SR, Elliot M, Lewinsohn DA et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-223.
13. Short MP, Choi BC, Lee JK et al. Gene delivery to glioma cells in rat brain by grafting of retrovirus packaging cell line. J Neurosci Res 1990;27:427-439.
14. Culver KW, Ram Z, Walbridge S et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-1552.
15. Takamiya Y, Short MP, Moolten FL et al. An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 1993;79:104-110.
16. Caruso M, Panis Y, Gagandeep S et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993;90:7024-7028.
17. Freeman SM, McCune C, Robinson W et al. The treatment of ovarian cancer with a gene modified cancer. A phase I study. Hum Gene Ther 1995;5:927-939.
18. Oldfield EH, Ram Z, Chiang Y et al. Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. GTI 0108. A phase I/II study. Hum Gene Ther 1995;6:55-85.
19. Klatzmann D, Valery CA, Bensimon G et al. A phase I/II dose escalation study of Herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Hum Gene Ther 1998;9:2595-2604.
20. Klatzmann D, Cherin P, Bensimon G et al. A phase I/II dose escalation study of Herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for melanoma. Hum Gene Ther 1998;9:2585-2594.
21. Bi WL, Parysek LM, Warnick R et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993;4:725-731.
22. Freeman SM, Abboud CN, Whartenby KA et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-5283.
23. Mesnil M, Piccolo C, Tribe G et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996;93:1831-1835.
24. Pruitt SK, Kirk AD, Bollinger RR et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994;57:363-370.
25. Platt JL, Vercellotti GM, Dalmaso AP et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990;17:456-457.
26. Galili U, Shohet SB, Kobrin E et al. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 1988;263:17755-17762.
27. Larsen RD, Rivera-Marrero CA, Ernst LK et al. Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal(1,4)-D-GlcNAc alpha(1,3)-galactosyl-transferase cDNA. J Biol Chem 1990;265:7055-7061.
28. Galili U. Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol 1993;15:155-171.
29. Sandrin MS, Vaughan HA, Dabkowski PL et al. Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. Proc Natl Acad Sci USA 1993;90:11391-11395.
30. Welsh RM, Cooper NR, Jensen FC et al. Human serum lyses RNA tumour viruses. Nature 1975;257:612-614.
31. Rother RP, Fodor WL, Springhorn JP et al. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J Exp Med 1995;182:1345-1355.
32. Link CJ, Levy JP, Seregina T et al. Protection of murine vector producer cells from complement mediated lysis by Lovenox and SCR1. In: Mazarakis H, Swart SJ, eds. Cancer Gene Therapy. London: IBC Library Series, 135-152.
33. Rother RP, Squinto SP, Mason JM et al. Protection of retroviral vector particles in the human blood through complement inhibition. Hum Gene Ther 1995;6:429-435.